LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.34 -6.62%

-$0.42 today

Market cap
$104.94M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.64M

Average 0.89M

Returns on capital

LENZ Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-28.9%

avg 181.0%

ROIC

-33.0%

avg -31.0%

ROA

-26.8%

avg -382.6%

Analysis

ROA is currently the strongest return metric at -26.8% versus its period average of -382.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Evert Schimmelpennink

President, Chief Executive Officer, Secretary & DirectorUSD 1.24M54——

Marc G. Odrich

Chief Medical OfficerUSD 774K67——

Shawn Olsson

Chief Commercial OfficerUSD 724.6K4314.00K0.04%

Daniel R. Chevallard

CFO, Principal Financial & Accounting OfficerUSD 680.37K47652.06K2.08%

James W. McCollum

Co-Founder & DirectorUSD 40K7122.10K0.07%

Kris Gambelin

Senior Vice President of Regulatory & Clincal Operations————

David Choromanski

Vice President of Marketing————

Domenick Porfidia

Vice President of Sales————

Melissa Rosness

Senior Vice President of Manufacturing Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 30, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$365,575.74

Sells

3

$9.13M

Net Transaction Value

−$8.77M

Net selling

Most Active

RA CAPITAL MANAGEMENT, L.P.

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 29, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$7.3M
Oct 29, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$1.5M
Oct 29, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$360.1K
Mar 27, 26

George Jeffrey P.

Direct

Buy$49.9K
Mar 27, 26

Schimmelpennink Evert B.

Direct

Buy$251.4K
Mar 27, 26

Chevallard Daniel R.

Direct

Buy$64.3K

Summary

Insiders reported 3 buys worth $365,575.74 and 3 sells worth $9.13M over the last 12 months. That adds up to net selling of $8.77M. RA CAPITAL MANAGEMENT, L.P. was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+8.4%
+45.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +8.4% over three years. Forward estimates point to Revenue at +45.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does LENZ Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about LENZ's management, answered from reported figures.

Who manages LENZ?

LENZ Therapeutics, Inc. (LENZ) lists 9 active executives. The top listed executive is Daniel R. Chevallard, CFO, Principal Financial & Accounting Officer.

Are LENZ insiders buying or selling?

Recent insider activity shows net selling of $9.57M.